Please login to the form below
Akorn
This page shows the latest Akorn news and features for those working in and with pharma, biotech and healthcare.
Data integrity scuppers Fresenius deal with Akorn
Akorn is furious about the decision, and says it intends to hold Fresenius to its obligations under the merger agreement. ... Akorn can claim a termination fee, which in the original merger agreement was valued at $129m.
Latest news
-
Fresenius says Akorn investigation could affect takeover
The company says it is conducting an independent investigation - using external experts - into “alleged breaches of FDA data integrity requirements relating to product development at Akorn”. ... Sales for Akorn’s small consumer health business
-
Fresenius Kabi buys Akorn and Merck's biosimilar businesses
Fresenius is paying $34 per share for Akorn - valuing the company at $4.3bn - and will also assume around $450m in debt held by the US firm. ... Rumours of a deal have been circulating for several weeks, and Akorn confirmed it was in negotiations with
-
Survival strategy
A recent example of Big Pharma's entry into the generic marketplace was the purchase by Pfizer in December of 22 abbreviated new drug applications for $56m from the Akorn-Strides ... 80. Akorn-Strides/Pfizer. Acquisition of 22 ANDAs in US. Registration.
More from news
Approximately 3 fully matching, plus 1 partially matching documents found.
Latest Intelligence
-
Deal Watch - May 2017
In addition at the end of 2016 Akorn had net debt of around $600m and operating cash flow of $168m. ... 6, 100. Akorn (US). Fresenius (DE). Company acquisition. Manufacturing facilities and generic ophthalmic products with $1.1bn sales.
-
Pharma deals during September 2014
The contract manufacturing sector is in a state of flux with the acquisition of Patheon last year by DSM and Akorn's acquisition of the ophthalmic manufacturer Excelvision in July this
-
Deal Watch table for June 2014
45. ECR Pharmaceuticals / Valeant. Company acquisition. Akorn subsidiary with branded generics business.
-
Deal Watch table for May 2014
VersaPharm / Akorn. Company acquisition. US generic company selling dermatology products with $100m sales.
-
Pharma deals during May 2014
Merck sold its US ophthalmic business in 2013 for 1.5 x sales to Akorn. ... Akorn is better known for its ophthalmic business where it acquired three products from Merck &Co in November 2013 for $53m.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
An agency called Owen
We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
